Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

(2022) Nabeel H. Akhtar et al.   Allergy Asthma and Clinical Immunology

Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series

(2021) A.L. Bosma et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic

(2021) K. Hansel et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in Italy

(2021) Luca Stingeni et al.   Dermatologic Therapy

COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review

(2021) Justyna Ceryn et al.   Clinical Cosmetic and Investigational Dermatology

The Use of Biologics During the COVID-19 Pandemic

(2021) Madison E. Jones et al.   DERMATOLOGIC CLINICS

Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study

(2021) Khalaf Kridin et al.   IMMUNOLOGIC RESEARCH

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab

(2021) Benjamin Ungar et al.   Journal of Allergy and Clinical Immunology-In Practice

Rapid, Cheap, and Effective COVID-19 Diagnostics for Africa

(2021) Lukman Yusuf et al.   Diagnostics

COVID ‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED‐ZONE declaration

(2020) Nicola Luigi Bragazzi et al.   Dermatologic Therapy

Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto

(2020) Jorge R. Georgakopoulos et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Should patients stop their biologic treatment during the COVID-19 pandemic

(2020) Arjun M. Bashyam et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Safety of dupilumab in atopic patients during COVID-19 outbreak

(2020) Maddalena Napolitano et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

SARS‐CoV‐2 asymptomatic infection in a patient under treatment with dupilumab

(2020) Francesca Caroppo et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety of dupilumab in severe atopic dermatitis and infection of Covid‐19: two case reports

(2020) S. Ferrucci et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis

(2020) Andreas Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID ‐19 pandemic: A single‐center real‐life experience

(2020) Mariateresa Rossi et al.   Dermatologic Therapy

Dupilumab in atopic dermatitis, a protocol for SARS‐COV 2 infected patients

(2020) Maria Fernanda Ordóñez‐Rubiano et al.   Dermatologic Therapy

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis

(2020) O. Baniandrés-Rodríguez et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

(2020) Marina Talamonti et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study

(2020) C. Patruno et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

(2019) Lieneke F. M. Ariëns et al.   ALLERGY

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

(2018) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis

(2014) Jennifer D. Hamilton et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE